{
    "clinical_study": {
        "@rank": "21730", 
        "arm_group": {
            "arm_group_label": "gevokizumab", 
            "arm_group_type": "Experimental", 
            "description": "Solution for subcutaneous injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy\n      in patients with steroid resistant Autoimmune Inner Ear Disease."
        }, 
        "brief_title": "The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Autoimmune Inner Ear Disease", 
        "condition_browse": {
            "mesh_term": [
                "Ear Diseases", 
                "Labyrinth Diseases", 
                "Labyrinthitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Autoimmune Inner Ear Disease with active deterioration in at least one ear\n\n          -  Failure to respond to a trial of high-dose corticosteroid therapy\n\n          -  Contraceptive measures adequate to prevent pregnancy during the study\n\n        Exclusion Criteria:\n\n          -  Evidence of retrocochlear pathology (vestibular schwannoma) or inner ear malformation\n             (Mondini Malformation or Enlarged Vestibular Aqueduct)\n\n          -  History of active or chronic infections\n\n          -  Currently receiving, or having received treatment for a malignancy in the past three\n             years\n\n          -  Hearing loss that coincides with significant, disabling episodes of vertigo\n\n          -  History of allergic or anaphylactic reactions to monoclonal antibodies\n\n          -  Female subjects who are pregnant, planning to become pregnant, have recently\n             delivered, or are breast-feeding\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950312", 
            "org_study_id": "X052180", 
            "secondary_id": "R33DC011827"
        }, 
        "intervention": {
            "arm_group_label": "gevokizumab", 
            "intervention_name": "gevokizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Autoimmune Inner Ear Disease", 
            "Inner Ear Disease", 
            "Meniere's Disease", 
            "Sudden Sensorineural Hearing Loss"
        ], 
        "lastchanged_date": "September 20, 2013", 
        "location": {
            "contact": {
                "last_name": "Andrea Vambutas, MD", 
                "phone": "718-470-7550"
            }, 
            "contact_backup": {
                "last_name": "Ginny Mullooly", 
                "phone": "718-470-7974"
            }, 
            "facility": {
                "address": {
                    "city": "New Hyde Park", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11040"
                }, 
                "name": "Long Island Jewish Medical Center, Hearing & Speech Center"
            }, 
            "investigator": {
                "last_name": "Andrea Vambutas, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improved hearing threshold, as defined by an improvement in either the PTA (Pure Tone Average) of >=5 dB (Decibel), or 12% in the WRS (Word Recognition Score)", 
            "safety_issue": "No", 
            "time_frame": "Day 28 to Day 84"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950312"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "XOMA (US) LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Feinstein Institute for Medical Research", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Institute on Deafness and Other Communication Disorders (NIDCD)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "XOMA (US) LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}